Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab prophylaxis for gout flares during allopurinol initiation
2008-005876-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canakinumab in gout and acute gout flare (3 arms), sponsored by Novartis. Started Nov 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2008-005876-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005876-28.